Success Story: Rapid EB1A Approval in 16 Days for a Taiwanese Senior Scientist Focused on Sustained-Release and Targeted Delivery
Client’s Testimonial:
“It's my pleasure to work with your firm.”
On December 24th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Scientist in the Field of Biomedical Engineering (Approval Notice).
General Field: Biomedical Engineering
Position at the Time of Case Filing: Senior Scientist
Country of Origin: Taiwan
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: December 24th, 2025
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
Some biomedical breakthroughs are defined by how reliably a therapy can be delivered, sustained, and translated into real treatment pathways. In this EB1A case, the client built a specialized record at the intersection of injectable drug formulation, sustained-release and targeted delivery systems, and translational pharmaceutical development, areas where technical precision directly shapes clinical feasibility. NAILG (North America Immigration Law Group) presented the case around that practical impact, showing how the client’s work moves beyond concept-level biomaterials into delivery strategies that other researchers and developers can adopt.
With a Ph.D. and an M.S. in Biomedical Engineering, the client’s investigations produced novel methods and original discoveries that elevated his standing within this niche. Rather than relying on broad claims of importance, the petition emphasized how his work created usable approaches for drug encapsulation, gene delivery, and tissue engineering applications, including innovations tied to neural tissue repair and regeneration. Competitive support from the National Science and Technology Council of Taiwan further reinforced that these lines of work were recognized as high-value and innovation-driven.
The client’s influence was also reflected in measurable research uptake. He authored 6 peer-reviewed journal articles, including 3 first-authored papers, and the petition highlighted that his citation performance placed him among the top 1% of most highly cited authors in the relevant delivery-systems space. This was framed not as a numbers-only argument, but as evidence that independent researchers consistently rely on his findings to inform and validate their own work.
Peer recognition extended beyond publications. The client was invited to serve as a journal reviewer at least 6 times, reflecting trust in his judgment to evaluate others’ research in aligned technical areas. NAILG presented this as foundational proof of his standing, showing that the same expertise driving the client’s original contributions was also being used by the field to uphold publication standards.
Recommender testimony captured the field-facing significance in direct terms:
"As a distinguished biomedical engineer, [Client] has made significant advancements in neural tissue engineering through multi-cue integration. His expertise in both nerve regeneration and scalable fabrication techniques positions him as a leader in the field."
With the evidence organized around originality, independent reliance, and sustained peer trust, the petition presented a clear EB1A profile built on contribution quality and real-world translational relevance.